发布时间：2026-01-22 14:11 At IMCAS 2026, Galderma will present findings supporting Sculptra’s regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7
Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane Shaype in shaping the chin, Restylane Lyft in improving jawline definition, Restylane Skinboosters in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme in correcting hollowing of the temples8-11
New data on the innovative neuromodulator Relfydess (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12
As a leader in injectable aesthetic innovation, Galderma will showcase its
=*=*=*=*=*=
当前为第1/21页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页